NASDAQ:ACAD
Citigroup initates Acadia Pharmaceuticals Inc (ACAD) rating to a Buy
Acadia Pharmaceuticals Inc’s recently made public that its EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. unloaded Company’s shares for reported ...
Analyzing Acadia Pharmaceuticals Inc (ACAD) After Recent Trading Activity
In a filing, Acadia Pharmaceuticals Inc revealed its EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. unloaded Company’s shares for reported ...
Analyzing Acadia Pharmaceuticals Inc (ACAD) After Recent Trading Activity
Acadia Pharmaceuticals Inc’s recently made public that its Director Daly James M unloaded Company’s shares for reported $0.67 million on ...
Decline in ACAD’s short interest indicates Bullish sentiment
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Acadia Pharmaceuticals ...
EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sale 3,498 shares of Acadia Pharmaceuticals Inc [ACAD]
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Acadia Pharmaceuticals ...
ACAD’s short interest surges to 8.75 million shares
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or ...
